Merck & Co. Inc. disclosed in its latest Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission that the Texas Supreme Court has granted Merck s petition for review and scheduled oral argument for January 20,…
During the first nine months of 2009, Merck & Co. Inc. spent approximately US$190 million in the aggregate in legal defense costs worldwide, including US$65 million in the third quarter of 2009.
The legal expenses were related to (i) the Vioxx…
Merck & Co. Inc. disclosed in its latest Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission that it is cooperating with U.S. Attorney s Office for the District of Massachusetts.
In March 2009, Merck received a…
Merck & Co. Inc. disclosed in its latest Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission that in the MDL proceeding of the Vioxx dispute, the trial of the Louisiana Attorney General case is scheduled…
Merck & Co. Inc. disclosed in its latest Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission that it continues to respond to the subpoena sent by the State of California Attorney General in connection with…
Merck & Co. Inc. disclosed in its latest Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission that on September 8, 2009, plaintiff filed a second motion for rehearing en banc regarding the Texas state court…
Merck & Co. Inc. disclosed in its latest Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission that it is cooperating with the U.S. Department of Justice regarding a probe centered on its Vioxx product activities.
The…
Merck & Co. Inc. disclosed in its latest Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission that it is cooperating with governmental entities in Europe in their respective investigations on the company’s Vioxx product.
Investigations are…
Merck & Co. Inc. disclosed in its latest Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission that As of September 30, 2009, the Company had been served or was aware that it had been named…
Merck & Co. Inc. disclosed in its latest Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission that as of June 30, 2009, the Company had been served or was aware that it had been named…